Merrimack Initiates Phase I MM-398 Trial

To evaluate cyclophosphamide combination in pediatric tumors

Merrimack Pharmaceuticals has initiated a Phase I dose-escalating trial of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors. Preclinical research suggests MM-398 administration results in sustained delivery of larger quantities of chemotherapy as compared to conventional administration.
 
The Phase I study will assess the safety of MM-398 and will determine the recommended Phase II dose. Approximately 40 patients from 1 to 21 years are expected to be enrolled.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters